癌变·畸变·突变
癌變·畸變·突變
암변·기변·돌변
CARCINOGENSES,TERATOGENSIS AND MUTAGENESIS
2013年
4期
272-275,279
,共5页
康贵云%李哲萍%刘晓丽%武希润%申慧琴%王琦
康貴雲%李哲萍%劉曉麗%武希潤%申慧琴%王琦
강귀운%리철평%류효려%무희윤%신혜금%왕기
1-D-甲基色氨酸%FOLFOX4%胃癌%调节性T细胞
1-D-甲基色氨痠%FOLFOX4%胃癌%調節性T細胞
1-D-갑기색안산%FOLFOX4%위암%조절성T세포
1-D-methyl tryptophan%FOLFOX4%gastric cancer%regulatory T cell
目的:研究FOLFOX4与1-D-甲基色氨酸(1-D-methyl tryptophan,1-D-MT)联合应用是否有利于改善荷胃癌小鼠的免疫耐受状态。方法:用脂质体转染法,将pcDNA3.1-IDO质粒和pcDNA3.1(+)空质粒稳定转染MFC细胞,并设未转染组;用RT-PCR和Western blot法检测未转染组、空质粒转染组和pcDNA3.1-IDO转染组IDO mRNA和蛋白的表达;然后建立荷胃癌小鼠皮下移植瘤模型,并设未转染组、空质粒转染组,IDO+生理盐水(NS)组、FOLFOX4组、1-D-MT组和FOLFOX4+1-D-MT联合处理组,采用流式细胞术检测各组小鼠脾脏中Treg细胞数量变化;RT-PCR检测FOXP3 mRNA表达量变化。结果:IDO mRNA与蛋白表达在稳定转染pcDNA3.1-IDO质粒组细胞较未转染组、空质粒转染组表达量明显增加(P<0.05)。IDO+NS组小鼠脾脏Treg细胞比例及FOXP3 mRNA含量较未转染组、空质粒组均明显增多(P<0.05)。FOLFOX4+1-D-MT组和1-D-MT组与FOLFOX4组相比,Treg细胞比例及FOXP3 mRNA含量均明显降低(P<0.05),且联合治疗组较1-D-MT组降低更明显(P<0.01)。结论:通过抑制Treg的增殖及降低FOXP3 mRNA表达,FOLFOX4与1-D-MT联合应用可降低机体免疫逃逸能力。
目的:研究FOLFOX4與1-D-甲基色氨痠(1-D-methyl tryptophan,1-D-MT)聯閤應用是否有利于改善荷胃癌小鼠的免疫耐受狀態。方法:用脂質體轉染法,將pcDNA3.1-IDO質粒和pcDNA3.1(+)空質粒穩定轉染MFC細胞,併設未轉染組;用RT-PCR和Western blot法檢測未轉染組、空質粒轉染組和pcDNA3.1-IDO轉染組IDO mRNA和蛋白的錶達;然後建立荷胃癌小鼠皮下移植瘤模型,併設未轉染組、空質粒轉染組,IDO+生理鹽水(NS)組、FOLFOX4組、1-D-MT組和FOLFOX4+1-D-MT聯閤處理組,採用流式細胞術檢測各組小鼠脾髒中Treg細胞數量變化;RT-PCR檢測FOXP3 mRNA錶達量變化。結果:IDO mRNA與蛋白錶達在穩定轉染pcDNA3.1-IDO質粒組細胞較未轉染組、空質粒轉染組錶達量明顯增加(P<0.05)。IDO+NS組小鼠脾髒Treg細胞比例及FOXP3 mRNA含量較未轉染組、空質粒組均明顯增多(P<0.05)。FOLFOX4+1-D-MT組和1-D-MT組與FOLFOX4組相比,Treg細胞比例及FOXP3 mRNA含量均明顯降低(P<0.05),且聯閤治療組較1-D-MT組降低更明顯(P<0.01)。結論:通過抑製Treg的增殖及降低FOXP3 mRNA錶達,FOLFOX4與1-D-MT聯閤應用可降低機體免疫逃逸能力。
목적:연구FOLFOX4여1-D-갑기색안산(1-D-methyl tryptophan,1-D-MT)연합응용시부유리우개선하위암소서적면역내수상태。방법:용지질체전염법,장pcDNA3.1-IDO질립화pcDNA3.1(+)공질립은정전염MFC세포,병설미전염조;용RT-PCR화Western blot법검측미전염조、공질립전염조화pcDNA3.1-IDO전염조IDO mRNA화단백적표체;연후건립하위암소서피하이식류모형,병설미전염조、공질립전염조,IDO+생리염수(NS)조、FOLFOX4조、1-D-MT조화FOLFOX4+1-D-MT연합처리조,채용류식세포술검측각조소서비장중Treg세포수량변화;RT-PCR검측FOXP3 mRNA표체량변화。결과:IDO mRNA여단백표체재은정전염pcDNA3.1-IDO질립조세포교미전염조、공질립전염조표체량명현증가(P<0.05)。IDO+NS조소서비장Treg세포비례급FOXP3 mRNA함량교미전염조、공질립조균명현증다(P<0.05)。FOLFOX4+1-D-MT조화1-D-MT조여FOLFOX4조상비,Treg세포비례급FOXP3 mRNA함량균명현강저(P<0.05),차연합치료조교1-D-MT조강저경명현(P<0.01)。결론:통과억제Treg적증식급강저FOXP3 mRNA표체,FOLFOX4여1-D-MT연합응용가강저궤체면역도일능력。
OBJECTIVE: To investigate whether combining 1-D-MT with FOLFOX4 could be useful to TMimprove the immune tolerance of gastric cancer-bearing mice. METHODS:By using the lipofectamine 2000,the eukaryotic expression plasmid pcDNA3.1-IDO and empty vector pcDNA3.1 (+) were transfected in a MFC cell line,setting a control group. The expression of IDO was detected by reverse transcription polymerase chain reaction(RT-PCR) and western blot. Animal model of gastric cancer-bearing mice were established to receive normal saline (NS),FOLFOX4,1-D-MT and 1-D-MT+FOLFOX4 therapy. By using flow cytometry,Treg cell ratio change was analyzed and FOXP3 mRNA expression change was assessed by RT-PCR. RESULTS:The expression of IDO mRNA and protein in the group trancfected with pcDNA3.1-IDO was obviousely ligher than the MFC group and the empty vector group (P<0.05). Treg cell ratio and FOXP3 mRNA expression in the transfected IDO negative control group with NS therapy was higher than the MFC and the empty vector groups (P<0.05). The Treg ratio and FOXP3 mRNA in 1-D-MT+FOLFOX4 and 1-D-MT groups were less than in FOLFOX4 group(P<0.05),with 1-D-MT+FOLFOX4 group more markedly than 1-D-MT group (P<0.05). CONCLUSION:Combining 1-D-MT with FOLFOX4 could reduce Treg cell ratio and FOXP3 expression,thus reducing the immune escape.